Home /
science Podcasts /
BiotechTV - News /
Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

EPISODE · May 16, 2025 · 14 MIN

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.

Episode metadata supplied by the publisher feed · Published May 16, 2025

Embed this episode

Attribution link and audio player

Ready to play

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

0:00 14:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 14 minutes long.

When was this BiotechTV - News episode published?

This episode was published on May 16, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!